Associated Papers
Differential Responses to Targeted Therapies in Non-Small Cell Lung Cancer: A Comparative Analysis of Outcomes in Patients with Single EGFR Mutation and Concurrent Gene Alterations.
Le LT et al.
The Application of Clinical Genetics, 2025
Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations.
Yasin F et al.
The Oncologist, 2024
Comparison between next-generation sequencing and multiplex polymerase chain reaction assays for nonsmall-cell lung cancer molecular diagnosis.
Murakami S et al.
Cancer Medicine, 2024
Somatic Mutations in Latin American Breast Cancer Patients: A Systematic Review and Meta-Analysis.
Martínez-Nava GA et al.
Diagnostics (basel, Switzerland), 2024
KRAS, NRAS, BRAF, and PIK3CA mutation rates, clinicopathological association, and their prognostic value in Iranian colorectal cancer patients.
Mirzapoor Abbasabadi Z et al.
Journal of Clinical Laboratory Analysis, 2023
NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment.
Sánchez-Herrero E et al.
Molecular Oncology, 2021
Clinical Application of Targeted Deep Sequencing in Metastatic Colorectal Cancer Patients: Actionable Genomic Alteration in K-MASTER Project.
Lee Y et al.
Cancer Research and Treatment, 2021
The Spectrum, Tendency and Predictive Value of PIK3CA Mutation in Chinese Colorectal Cancer Patients.
Fu X et al.
Frontiers in Oncology, 2021
Divergent molecular profile of PIK3CA gene in arsenic-associated bladder carcinoma.
Basu M et al.
Mutagenesis, 2020
Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer.
Huang RSP et al.
The Oncologist, 2020
Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review.
Guo Y et al.
Frontiers in Oncology, 2020
Mutation profiling of cancer drivers in Brazilian colorectal cancer.
Dos Santos W et al.
Scientific Reports, 2019
Targeted deep sequencing from multiple sources demonstrates increased NOTCH1 alterations in lung cancer patient plasma.
Liao Y et al.
Cancer Medicine, 2019
Genotyping of Circulating Tumor DNA Reveals the Clinically Actionable Mutation Landscape of Advanced Colorectal Cancer.
Cao W et al.
Molecular Cancer Therapeutics, 2019
Comparison of TCGA and GENIE genomic datasets for the detection of clinically actionable alterations in breast cancer.
Kaur P et al.
Scientific Reports, 2019
Long-term clinical benefit from salvage EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer patients with EGFR wild-type tumors.
Koinis F et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2018
Coexistence of EGFR, KRAS, BRAF, and PIK3CA Mutations and ALK Rearrangement in a Comprehensive Cohort of 326 Consecutive Spanish Nonsquamous NSCLC Patients.
Martín Martorell P et al.
Clinical Lung Cancer, 2017
High performance of targeted next generation sequencing on variance detection in clinical tumor specimens in comparison with current conventional methods.
Su D et al.
Journal of Experimental & Clinical Cancer Research : Cr, 2017
Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study.
Jauhri M et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine, 2017
PIK3CA mutations in HER2-positive Breast Cancer Patients; Frequency and Clinicopathological Perspective in Egyptian Patients
Elwy F et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2017
Molecular evaluation of PIK3CA gene mutation in breast cancer: determination of frequency, distribution pattern and its association with clinicopathological findings in Indian patients.
Ahmad F et al.
Medical Oncology (northwood, London, England), 2016
Cytotoxicity of allitinib, an irreversible anti-EGFR agent, in a large panel of human cancer-derived cell lines: KRAS mutation status as a predictive biomarker.
Silva-Oliveira RJ et al.
Cellular Oncology (dordrecht, Netherlands), 2016
Rapid targeted somatic mutation analysis of solid tumors in routine clinical diagnostics.
Magliacane G et al.
Oncotarget, 2015
Identification of KRAS and PIK3CA but not BRAF mutations in patients with gastric cancer.
Lu W et al.
Molecular Medicine Reports, 2015
Molecular spectrum of PIK3CA gene mutations in patients with nonsmall-cell lung cancer in Turkey.
Ekinci S et al.
Genetic Testing and Molecular Biomarkers, 2015
Occurrence of low frequency PIK3CA and AKT2 mutations in gastric cancer.
Zhang QY et al.
Mutation Research, 2014
PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup.
Wang L et al.
Plos One, 2014
Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia.
Palomba G et al.
Journal of Translational Medicine, 2012
Pancreatic endocrine tumours: mutational and immunohistochemical survey of protein kinases reveals alterations in targetable kinases in cancer cell lines and rare primaries.
Corbo V et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2012
KRAS, BRAF and PIK3CA mutations and the loss of PTEN expression in Chinese patients with colorectal cancer.
Mao C et al.
Plos One, 2012
PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients.
Perrone F et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2009